Medicaid

Latest KFF Health News Stories

GOP Health Bill’s Changes Go Far Beyond Preexisting Conditions

KFF Health News Original

The measure proposed by Sens. Lindsey Graham (R-S.C.) and Bill Cassidy (R-La.) would disrupt the existing health system more than any of the measures considered so far this year, according to supporters and critics.

For Low-Income Drug Users, Medi-Cal Offers A Fresh Start

KFF Health News Original

Under a five-year agreement with the federal government, California is using Medicaid dollars to expand drug treatment, including more inpatient care and a broader range of medications.

Con el fin de DACA, jóvenes inmigrantes temen por su salud

KFF Health News Original

La polémica decisión de la administración Trump de eliminar el programa DACA hace más que poner a casi 800.000 “dreamers” bajo el miedo a la deportación. Amenaza el cuidado de salud de miles de adultos jóvenes.

Move To End DACA Leaves Some Young Immigrants Fearing For Their Health

KFF Health News Original

The Deferred Action for Childhood Arrivals program made it possible for young adults who came into the country illegally as children to get jobs with insurance and, in some states including California, Medicaid. Now that coverage is in peril.   

5 Outside-The-Box Ideas For Fixing The Individual Insurance Market

KFF Health News Original

As lawmakers look for ways to stabilize the health law marketplaces, a number of ideas — such as expanding who can “buy in” to Medicare and Medicaid or pushing young adults off their parents’ plans into the marketplaces — might come into play.

S.C. Taps Private Donors To Expand In-Home Services For At-Risk Moms

KFF Health News Original

The expansion of the Nurse-Family Partnership, financed initially by the federal government and several philanthropies, must meet specific goals to get state contributions. Officials hope to add 3,200 women to the program.

Drug Puts A $750,000 ‘Price Tag On Life’

KFF Health News Original

The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.